William G. Wierda
Impact in
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.02%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Papers in
- Genetics 680
- Chronic Lymphocytic Leukemia Research 659
- Hematology 277
- Chronic Myeloid Leukemia Treatments 181
- Acute Myeloid Leukemia Research 104
- Co-authors
- Michael J. Keating (251 shared papers)Hagop Kantarjian (251 shared papers)Susan Mary O'Brien (202 shared papers)Jörge E. Cortes (188 shared papers)Alessandra Ferrajoli (251 shared papers)Jan A. Burger (190 shared papers)Guillermo Garcia‐Manero (157 shared papers)Stefan H Faderl (143 shared papers)
- Journals
- Blood (419 papers)Cancer (55 papers)Leukemia (37 papers)Journal of Clinical Oncology (26 papers)British Journal of Haematology (26 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
William G. Wierda
876 papers receiving 53.5k citations
William G. Wierda's Hit Papers
Peers
Comparison fields: 5 of 150
- Genetics 29.2k
- Hematology 15.2k
- Pathology and Forensic Medicine 19.7k
- Immunology 13.4k
- Oncology 14.1k
Countries citing papers authored by William G. Wierda
This map shows the geographic impact of William G. Wierda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William G. Wierda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William G. Wierda more than expected).
Fields of papers citing papers by William G. Wierda
This network shows the impact of papers produced by William G. Wierda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William G. Wierda. The network helps show where William G. Wierda may publish in the future.
Co-authors
The 25 scholars most cited alongside William G. Wierda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 905 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities Hit paper breakdown → | 2017 | 1954 |
| 2 | Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2013 | 1942 |
| 3 | Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Hit paper breakdown → | 2020 | 1743 |
| 4 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2015 | 1593 |
| 5 | Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia Hit paper breakdown → | 2005 | 781 |
| 6 | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2015 | 778 |
| 7 | Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease Hit paper breakdown → | 2011 | 720 |
| 8 | Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity Hit paper breakdown → | 2017 | 689 |
| 9 | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Hit paper breakdown → | 2016 | 686 |
| 10 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Hit paper breakdown → | 2021 | 627 |
| 11 | Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Hit paper breakdown → | 2017 | 621 |
| 12 | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib Hit paper breakdown → | 2015 | 584 |
| 13 | 2006 | 583 | |
| 14 | 2008 | 574 | |
| 15 | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo Hit paper breakdown → | 2011 | 561 |
| 16 | 2006 | 526 | |
| 17 | Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial Hit paper breakdown → | 2020 | 493 |
| 18 | 2010 | 476 | |
| 19 | 2011 | 474 | |
| 20 | 2006 | 440 |
About William G. Wierda
William G. Wierda is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Public Health, Environmental and Occupational Health, having authored 905 papers that have together received 54.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (659 papers), Lymphoma Diagnosis and Treatment (300 papers), Chronic Myeloid Leukemia Treatments (181 papers), Acute Lymphoblastic Leukemia research (165 papers), Immunodeficiency and Autoimmune Disorders (148 papers), Acute Myeloid Leukemia Research (104 papers), CAR-T cell therapy research (62 papers) and Advanced Breast Cancer Therapies (42 papers). The work is most often cited by research in Genetics (29.2k citations), Hematology (15.2k citations), Pathology and Forensic Medicine (19.7k citations), Immunology (13.4k citations) and Oncology (14.1k citations). William G. Wierda has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Michael J. Keating, Hagop Kantarjian, Susan Mary O'Brien, Jörge E. Cortes, Alessandra Ferrajoli, Jan A. Burger, Guillermo Garcia‐Manero, Stefan H Faderl, Susan Mary O'Brien and Thomas J. Kipps. Their work appears in journals such as Blood, Cancer, Leukemia, Journal of Clinical Oncology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.